Senseonics Reports Record 2025 Revenue, Strong Patient Growth, and Projects 65-76% Revenue Increase for 2026
Summary
Senseonics Holdings announced preliminary record revenues for Q4 and full-year 2025, significant patient growth, and provided robust 2026 revenue guidance projecting 65-76% growth, driven by strategic commercialization changes and product development.
Key Events
-
Record 2025 Revenue
Reported preliminary unaudited revenue of approximately $14.2 million for Q4 2025 (71% YOY increase) and $35.2 million for full-year 2025 (57% YOY increase), marking the largest quarterly and annual revenue in company history.
-
Strong 2026 Revenue Guidance
Projected full-year 2026 global net revenue to be between $58 million and $62 million, representing a substantial increase of 65% to 76% over 2025 revenue, with an expected gross margin of approximately 50%.
-
Significant Patient Growth
Achieved 103% new patient growth in the U.S. during Q4 2025 compared to Q4 2024, driven by direct-to-consumer marketing efforts.
-
Strategic Commercialization Shift
Executed agreements with Ascensia Diabetes Care to take over commercialization and distribution of Eversense® in the U.S. starting January 1, 2026, which is expected to lead to higher revenue and improved gross margins.
Analysis
The filing indicates strong operational momentum and a positive outlook for Senseonics. The preliminary 2025 revenues represent the highest in company history, coupled with substantial patient base expansion. The 2026 revenue guidance, projecting significant year-over-year growth, suggests a strong trajectory, partly due to the strategic transition of commercialization rights for Eversense. Additionally, the FDA IDE approval for the Gemini sensor pivotal trial marks a key advancement in product development, reinforcing the company's long-term potential.
At the time of this filing, SENS was trading at $7.10 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $290.9M. The 52-week trading range was $5.25 to $28.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.